An Open-label (Stage 1) and Randomized (Stage 2), 24 Month Study of Safety and Efficacy of Bimatoprost Drug Delivery System in Patients With Open-Angle Glaucoma or Ocular Hypertension
An Open-label (Stage 1) and Randomized (Stage 2), 24 Month Study of Safety and Efficacy of Bimatoprost Drug Delivery System in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of new ophthalmic formulations of bimatoprost in patients with open angle glaucoma and ocular hypertension. At least 3 dose strengths will be evaluated based on internal data review of each cohort. The study was planned to be conducted in 2 stages. Stage 1 was an open-label and Stage 2 was planned to be masked; however only Stage 1 was conducted.
Inclusion Criteria:
Exclusion Criteria:
La Jolla, California 92093, United States
Winchester, Massachusetts 01890, United States
Sydney New South Wales, 2000, Australia
Dienst Oogheelkunde, Leuven 3000, Belgium
São Paulo, 04023-062, Brazil
Rohovot, 76100, Israel
Metro Manila, Quezon City 1112, Philippines